pre-IPO PHARMA
COMPANIES VC JOBS NEWS CONTACT

viiv-healthcare PRESS RELEASE ARCHIVE

Feb 23, 2023

ViiV Healthcare Announces Positive Data Demonstrating Long-acting Injectable Cabenuva (cabotegravir, rilpivirine) is as Effective as Daily Oral Biktarvy (BIC/FTC/TAF) for the Treatment of HIV-1

Feb 14, 2023

ViiV Healthcare to present first head-to-head data for long-acting HIV treatment Cabenuva against daily oral Biktarvy at CROI 2023

Nov 30, 2022

ViiV Healthcare Unveils a New Global Study Revealing Three Quarters of People Believe There Are Still Negative Perceptions When It Comes to People Living With HIV

Oct 25, 2022

ViiV Healthcare presents positive proof-of-concept findings for N6LS, an investigational, broadly neutralising antibody (bNAb) offering a potential new approach for the treatment of HIV

Oct 24, 2022

ViiV Healthcare Presents Positive Data Showing Vocabria (cabotegravir) and Rekambys (rilpivirine) Can Be Successfully Implemented Across a Range of European Healthcare Settings

Jul 29, 2022

ViiV Healthcare presents positive five-year data at AIDS 2022, demonstrating the durability of fostemsavir in people living with HIV who are heavily treatment-experienced

Jul 28, 2022

ViiV Healthcare and the Medicines Patent Pool Sign New Voluntary Licensing Agreement to Expand Access to Innovative Long-Acting HIV Prevention Medicine

Jul 28, 2022

ViiV Healthcare Announces New Data at AIDS 2022 From Unblinded Phase of HPTN 084 Study in Women in Sub-Saharan Africa Showing Continued Superior Efficacy of Injectable Cabotegravir Long-Acting for PrEP Over Daily, Oral TDF/FTC Tablets

Mar 29, 2022

ViiV Healthcare Announces US FDA Approval of Cabenuva (cabotegravir, rilpivirine) for Virologically Suppressed Adolescents Living With HIV Who Are 12 Years of Age or Older and Weigh at Least 35 kg

Mar 24, 2022

ViiV Healthcare announces label update for its long-acting HIV treatment, Cabenuva (cabotegravir, rilpivirine), to be initiated with or without an oral lead-in period

Mar 24, 2022

ViiV Healthcare Announces Label Update for Its Long-Acting HIV Treatment, Cabenuva (cabotegravir, rilpivirine), to Be Initiated With or Without an Oral Lead-in Period

Feb 7, 2022

ViiV Healthcare to present new long-term findings from its innovative 2-drug and long-acting HIV medicines portfolio at CROI 2022

Feb 1, 2022

ViiV Healthcare Announces US FDA Approval of Cabenuva (cabotegravir, rilpivirine) for Use Every Two Months, Expanding the Label of the First and Only Complete Long-Acting HIV Treatment

Dec 21, 2021

HPTN Studies Inform FDA’s Approval of ViiV Healthcare’s Long-Acting Cabotegravir Injections for HIV Prevention

Dec 20, 2021

ViiV Healthcare announces US FDA approval of Apretude (cabotegravir extended-release injectable suspension), the first and only long-acting injectable option for HIV prevention

Oct 28, 2021

ViiV Healthcare presents positive interim data showing Vocabria (cabotegravir) and Rekambys (rilpivirine), the first long-acting HIV-treatment regimen, can be implemented successfully in a variety of European healthcare settings

Oct 28, 2021

ViiV Healthcare announces European Commission Decision for Vocabria (cabotegravir) and Rekambys (rilpivirine) injections to be initiated with or without an oral lead-in period for the long-acting treatment of HIV

Oct 20, 2021

Less Talk, More Action: New Report Sponsored by ViiV Healthcare Provides Roadmap to Achieve Health Equity by 2040

Sep 29, 2021

ViiV Healthcare presents three-year switch data for Dovato (dolutegravir/lamivudine) confirming long-term, non-inferior efficacy with no virologic failure versus continuation of TAF-based regimens of at least three drugs

Sep 28, 2021

FDA grants Priority Review to ViiV Healthcare’s New Drug Application for cabotegravir long-acting for prevention of HIV

Sep 28, 2021

ViiV Healthcare announces exclusive license agreement with Shionogi to develop third-generation HIV integrase inhibitor with potential for ultra long-acting dosing intervals

Jul 17, 2021

ViiV Healthcare study shows new long-acting HIV regimen Cabenuva (cabotegravir/rilpivirine) can be successfully implemented in broad range of US healthcare practices, even during COVID-19

Jul 17, 2021

ViiV Healthcare presents data from second Dovato (dolutegravir/lamivudine) switch study confirming non-inferior efficacy and no virologic failure versus a broad range of regimens of at least 3 drugs

Jun 22, 2021

ViiV Healthcare and Halozyme enter global collaboration and license agreement for ENHANZE drug delivery technology to enable development of “ultra long-acting” medicines for HIV

Jun 22, 2021

ViiV Healthcare and Halozyme enter global collaboration and license agreement for ENHANZE drug delivery technology to enable development of "ultra-long-acting" medicines for HIV

May 4, 2021

ViiV Healthcare initiates rolling submission of new drug application with US FDA for long-acting cabotegravir for prevention of HIV

Mar 9, 2021

ViiV Healthcare presents positive proof-of-concept findings for GSK3640254, a novel, investigational maturation inhibitor for the treatment of HIV

Feb 24, 2021

ViiV Healthcare Submits Supplemental New Drug Application to US FDA for Expanded Use of Cabenuva (cabotegravir, rilpivirine) as an HIV Treatment for Use Every 2-Months

Feb 8, 2021

ViiV Healthcare receives Marketing Authorisation for Rukobia (fostemsavir), a first-in-class attachment inhibitor in combination with other antiretrovirals for the treatment of adults with multidrug-resistant HIV

Jan 21, 2021

ViiV Healthcare announces FDA approval of Cabenuva (cabotegravir, rilpivirine), the first and only complete long-acting regimen for HIV treatment

Jan 21, 2021

ViiV Healthcare announces FDA approval of Cabenuva (cabotegravir, rilpivirine), the first and only complete long-acting regimen for HIV treatment

Dec 21, 2020

ViiV Healthcare announces the Marketing Authorisation of the first complete long-acting injectable HIV treatment in Europe

Dec 11, 2020

ViiV Healthcare Announces Positive CHMP Opinion for Rukobia (fostemsavir), a First-in-Class Attachment Inhibitor for the Treatment of Adults With Multidrug-Resistant HIV With Few Treatment Options Available

Dec 1, 2020

ViiV Healthcare and Shutterstock Studios unite to tackle outdated perceptions of HIV with ‘HIV in View’ - a first-of-its-kind online HIV photography gallery

Dec 1, 2020

ViiV Healthcare and Shutterstock Studios unite to tackle outdated perceptions of HIV with 'HIV in View'--a first-of-its-kind online HIV photography gallery

Nov 17, 2020

ViiV Healthcare receives FDA Breakthrough Therapy Designation for investigational, long-acting cabotegravir for HIV prevention

Nov 9, 2020

ViiV Healthcare announces investigational injectable cabotegravir is superior to oral standard of care for HIV prevention in women

Oct 16, 2020

ViiV Healthcare receives positive CHMP opinion for long-acting regimen for the treatment of HIV

Oct 8, 2020

ViiV Healthcare presents long-term switch data for Dovato demonstrating non-inferior efficacy in adults with HIV-1 and zero cases of virologic failure versus continuation of a 3-drug TAF-based regimen

Oct 5, 2020

ViiV Healthcare announces dolutegravir plus lamivudine three-year data confirming long-term viral suppression non-inferior to a 3-drug regimen for treatment-naïve adults with HIV-1

Sep 15, 2020

ViiV Healthcare Announces New Research Report, “Here as I Am,” on Socio-Economic Forces Affecting Access to HIV Care for Latinx Gay and Bisexual Men

Aug 6, 2020

ViiV Healthcare announces FDA approval of an expanded indication for Dovato (dolutegravir/lamivudine), a complete two-drug regimen for virologically suppressed adults with HIV-1

Jul 7, 2020

ViiV Healthcare Announces Superior Efficacy of Investigational, Long-Acting Injectable Formulation of Cabotegravir Dosed Every Two Months Over Daily Oral PrEP

Jul 2, 2020

ViiV Healthcare Announces US FDA Approval for Rukobia (fostemsavir), a First-in-Class Treatment for HIV in Adults With Few Treatment Options Available

Jul 2, 2020

ViiV Healthcare Announces US FDA Approval for Rukobia (fostemsavir), a First-in-Class Treatment for HIV in Adults With Few Treatment Options Available

Jun 12, 2020

ViiV Healthcare announces US FDA approval of the first-ever dispersible tablet formulation of dolutegravir, Tivicay PD, a once-daily treatment for children living with HIV

May 18, 2020

Global HIV prevention study to stop early after ViiV Healthcare’s long-acting injectable formulation of cabotegravir dosed every two months shows higher efficacy than daily oral PrEP

Apr 27, 2020

ViiV Healthcare announces £3 million global fund to research the impact of COVID-19 on the HIV community and fill gaps in prevention, treatment and care during the pandemic

Mar 20, 2020

ViiV Healthcare Announces First Global Regulatory Approval of CABENUVA; the First Complete, Long-acting, Regimen for the Treatment of HIV

Mar 9, 2020

ViiV Healthcare presents positive 48-week data from phase III study showing every-two-month regimen of investigational long-acting, injectable cabotegravir and rilpivirine has similar efficacy to once-monthly dosing

Mar 9, 2020

ViiV Healthcare and UNC-Chapel Hill announce five-year renewal of innovative HIV cure partnership

Mar 9, 2020

ViiV Healthcare presents positive long-term data from phase III study demonstrating efficacy and safety of cabotegravir and rilpivirine, its investigational, long-acting, injectable treatment regimen in adults living with HIV-1

Mar 2, 2020

ViiV Healthcare initiates study with the University of South Carolina to evaluate the benefits of ride-sharing services on improving access to care for people living with HIV

Jan 10, 2020

ViiV Healthcare submits regulatory application to the European Medicines Agency for fostemsavir, an investigational, first-in-class attachment inhibitor for the treatment of HIV in adults with few treatment options available

Dec 21, 2019

ViiV Healthcare receives complete response letter from US FDA for use of investigational cabotegravir and rilpivirine long-acting regimen in the treatment of HIV

Dec 5, 2019

ViiV Healthcare submits New Drug Application to the FDA for fostemsavir, an investigational, first-in-class attachment inhibitor for the treatment of HIV in adults with few treatment options available

Nov 21, 2019

ViiV Healthcare announces exclusive licensing agreement with the National Institutes of Health for investigational “bNAb” with potential for long-acting HIV treatment and prevention

Oct 16, 2019

ViiV Healthcare Submits Supplemental New Drug Application to US FDA for Use of Dovato in Virologically Suppressed Adults with HIV-1

Aug 22, 2019

ViiV Healthcare Reports Positive Phase III Study Results of Investigational, Long-acting, Injectable HIV-Treatment Regimen Administered Every Two Months

Jul 29, 2019

ViiV Healthcare Submits Regulatory Application to European Medicines Agency for Investigational Cabotegravir to Be Used in Combination With Rilpivirine as the First Monthly, Injectable Treatment for HIV

Jul 24, 2019

ViiV Healthcare announces positive Week 48 results in first study to evaluate treatment switch from TAF-containing regimen with three or more drugs to 2-drug regimen of dolutegravir/lamivudine for HIV-1 infection

Jul 24, 2019

ViiV Healthcare presents GEMINI 1 and 2 studies through Week 96 showing 2-drug regimen of dolutegravir plus lamivudine continues to demonstrate high efficacy rates and no cases of treatment emergent resistance

Jul 22, 2019

ViiV Healthcare presents positive 96-week data from phase III study of investigational fostemsavir in heavily treatment-experienced patients with HIV at IAS 2019

Jul 10, 2019

ViiV Healthcare announces phase III study meets primary endpoint, demonstrating the ability to control HIV-1 with a 2-drug regimen of dolutegravir plus lamivudine in virally suppressed patients switching from a TAF-containing, 3-drug regimen

Jul 3, 2019

ViiV Healthcare receives EU Marketing Authorisation for Dovato (dolutegravir/lamivudine), a new once-daily, single-pill, two-drug regimen for the treatment of HIV-1 infection

Apr 29, 2019

ViiV Healthcare Submits New Drug Application to US FDA for the First Monthly, Injectable, Two-Drug Regimen of Cabotegravir and Rilpivirine for Treatment of HIV

Apr 8, 2019

US FDA approves ViiV Healthcare’s Dovato (dolutegravir/lamivudine), the first, once-daily, single-tablet, two-drug regimen for treatment-naïve HIV-1 adults

Mar 7, 2019

ViiV Healthcare Presents Positive, 48-Week Data from Two Pivotal Phase III Studies Showing Long-Acting, Injectable Two-Drug Regimen of Cabotegravir and Rilpivirine Has Similar Efficacy to Daily, Three-Drug Oral Treatment in Adults Living with HIV-1 Infection

Jul 24, 2018

ViiV Healthcare Presents Phase III Data at AIDS 2018 from Landmark GEMINI Studies Showing Two-Drug Regimen of Dolutegravir and Lamivudine Has Similar Efficacy to a Three-Drug Regimen in Treatment Naïve HIV Patients, with No Emergence of Resistance

Jul 24, 2018

ViiV Healthcare announces SWORD 100-week data for Juluca (dolutegravir/rilpivirine) at AIDS 2018

Jul 18, 2018

ViiV Healthcare Shares Data from Landmark 2-Drug Regimen Trials At AIDS 2018

Jun 25, 2018

bioMONTR Labs Announces Laboratory Service Agreement With ViiV Healthcare

May 21, 2018

ViiV Healthcare Receives EU Marketing Authorisation for Juluca (dolutegravir/rilpivirine), the First 2-Drug Regimen, Once-Daily, Single-Pill for the Treatment of HIV

Mar 23, 2018

ViiV Healthcare Gains CHMP Positive Opinion for Juluca (dolutegravir/rilpivirine) in Europe

Jul 25, 2017

ViiV Healthcare Announces Superior Efficacy of Dolutegravir Versus Lopinavir/Ritonavir in Second-line HIV Treatment in Resource-limited Settings

Jan 25, 2017

bioMONTR Labs Announces Laboratory Service Agreements with ViiV Healthcare

Aug 16, 2016

ViiV Healthcare Launches Phase III Programme Evaluating a Two-drug Regimen Combining Dolutegravir and Lamivudine for HIV-1 Treatment

Jun 10, 2016

ViiV Healthcare Announces FDA Approval to Lower the Weight Limit for dolutegravir in Children and Adolescents Living With HIV

May 31, 2016

ViiV Healthcare and the International Association of Providers of AIDS Care (IAPAC) to Collaborate on Fast-Track Cities

Apr 25, 2016

ViiV Healthcare, Medicines Patent Pool Extend Licence for Dolutegravir to All Lower Middle-Income Countries

Apr 25, 2016

ViiV Healthcare et Medicines Patent Pool étendent la licence du Dolutegravir à tous les pays à revenu intermédiaire de la tranche inférieure

Feb 24, 2016

ViiV Healthcare Announces First Phase II HIV Prevention Study Results for Investigational Long-acting Injectable Cabotegravir

Feb 23, 2016

ViiV Healthcare Announces Phase II Study Results for First Two Drug, Long-acting Injectable Regimen for HIV-1 Treatment

Feb 22, 2016

Bristol-Myers Squibb Completes Previously Announced Sale of its HIV RandD Portfolio to ViiV Healthcare

Jan 19, 2016

ViiV Healthcare & the Los Angeles Department of Health Services Announce New Fellowship Program to Address a Growing Shortage of Primary Care HIV Specialists

Jan 7, 2016

ViiV Healthcare to Progress Collaboration with Janssen to Develop the First Long-acting, Two Drug Injectable Regimen for Treatment of HIV-1 Infection

Jan 7, 2016

Janssen to Progress Collaboration with ViiV Healthcare to Develop the First Long Acting Two Drug Injectable Regimen for Treatment of HIV Infection

Dec 18, 2015

Bristol-Myers Squibb to Sell its HIV RandD Portfolio to ViiV Healthcare

Nov 3, 2015

ViiV Healthcare Announces Positive Headline Results from a Study of Two Drug Injectable Regimen for HIV Maintenance Therapy

Oct 26, 2015

ViiV Healthcare Awards 23 Small Grants to Help Alleviate the Stigma of HIV and AIDS in the MSM and Transgender Community Globally

Jul 2, 2015

ViiV Healthcare and Desano Pharmaceuticals' Manufacturing Agreement Will Allow Competitive Supply of Dolutegravir in China and Several Developing Countries

May 26, 2015

ViiV Healthcare and CHAI Collaboration Delivers Second Milestone With First Filing With the FDA of Generic Dolutegravir by Aurobindo Pharma for the Treatment of HIV

May 6, 2015

ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy

Feb 4, 2015

ViiV Healthcare Announces $10 Million Initiative to Accelerate Response to HIV/AIDS Among Black Gay and Bisexual Men

Dec 4, 2014

Mylan receives tentative FDA approval for paediatric formulations of abacavir/lamivudine through innovative collaboration with ViiV Healthcare and Clinton Health Access Initiative

Oct 20, 2014

ViiV Healthcare Expands Program to Reduce HIV Disparities in Southern U.S.

Aug 25, 2014

Multimedia assets now available: ViiV Healthcare receives FDA approval for Triumeq® (abacavir, dolutegravir and lamivudine), a new single-pill regimen for the treatment of HIV-1 infection

Aug 25, 2014

ViiV Healthcare recibe aprobación de la FDA para Triumeq (abacavir, dolutegravir y lamivudine), una nueva régimen de tableta única para el tratamiento de la infección por VIH-1

Aug 22, 2014

ViiV Healthcare receives FDA approval for Triumeq® (abacavir, dolutegravir and lamivudine), a new single-pill regimen for the treatment of HIV-1 infection

Jun 12, 2014

ViiV Healthcare announces new collaboration with Janssen to investigate single-tablet regimen for maintenance treatment of HIV-1

Jun 12, 2014

Janssen Collaborates With ViiV Healthcare to Develop Two-Drug Single Tablet Regimen for the Maintenance Treatment of People Living With HIV

Apr 1, 2014

ViiV Healthcare announces new initiatives to improve access to dolutegravir: licence to the Medicines Patent Pool

Apr 1, 2014

Medicines Patent Pool, ViiV Healthcare Sign Licence for the Most Recent HIV Medicine to Have Received Regulatory Approval

Mar 19, 2014

ViiV Healthcare Announces Next Round of the Positive Action Southern Initiative to Support Linkages to HIV/AIDS Care and Treatment Adherence

Jan 21, 2014

ViiV Healthcare's new HIV medicine Tivicay™ (dolutegravir) is approved in Europe

Sep 12, 2013

ViiV Healthcare Presents Positive Data from Phase IIIb/IV Study of Dolutegravir vs Darunavir in Treatment-Naive Adults with HIV-1

Sep 4, 2013

ViiV Healthcare Expands HIV/AIDS Community Support in Hard-Hit Southern U.S.

Aug 14, 2013

ViiV Healthcare anuncia la aprobación de Tivicay (dolutegravir) en EE. UU. para el tratamiento del VIH-1

Jul 18, 2012

ViiV Healthcare Expands Commitment to Addressing Gaps in Paediatric HIV Research, Care and Treatment

Jul 11, 2012

Shionogi-ViiV Healthcare announces positive initial data from phase III study of dolutegravir-based regimen vs Atripla in HIV

Apr 2, 2012

Shionogi-ViiV Healthcare Announces Initial Data from Pivotal Phase III Study of Dolutegravir in HIV

Feb 7, 2012

Siemens Forms New Companion Diagnostics Partnerships with ViiV Healthcare and Tocagen

Oct 12, 2011

'ViiV Healthcare Effect' Brings ViiV Healthcare's Positive Action Partnerships to Life

Oct 11, 2011

ViiV Healthcare Starts Phase III Clinical Programme of Celsentri/Selzentry® (maraviroc) versus Truvada® (tenofovir + FTC), in combination with a Protease Inhibitor in people living with HIV

Nov 23, 2010

Idenix Pharmaceuticals Announces $20 Million Milestone Payment From ViiV Healthcare for Initiation of Phase IIb Trial of '761

Oct 21, 2010

Shionogi-ViiV Healthcare LLC Initiates Phase III Clinical Programme for Investigational Once-Daily HIV Integrase Inhibitor

Oct 12, 2010

ViiV Healthcare Acts to Improve Access to HIV Medicines in United States for Those Most in Need

Jul 22, 2010

Shionogi-ViiV Healthcare LLC Presents Positive Data on Investigational Once-Daily Integrase Inhibitor at International AIDS Conference

Jul 21, 2010

Shionogi-ViiV Healthcare Announces Commitment to Phase III Development Program for Investigational Once-Daily HIV Integrase Inhibitor

Jun 7, 2010

ViiV Healthcare and Elizabeth Glaser Pediatric AIDS Foundation Partner to Expedite Access to ARV Treatment for Infants and Children

Feb 22, 2010

ViiV Healthcare Presents New Data from HIV/AIDS Portfolio Demonstrating Research Advances and Commitment to Patient Care at Conference on Retroviruses and Opportunistic Infections

Google Analytics Alternative